Very early researchNot Yet RecruitingNCT07458919What this trial is testingTherapy for Advanced NSCLC With EGFR 19delins MutationWho this might be right forLung Cancer Fuzhou General Hospital 94
Testing effectiveness (Phase 2)Study completedNCT01260181What this trial is testingErlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor MutationsWho this might be right forNon-Squamous Non-Small Cell Lung Cancer Hoffmann-La Roche 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT06303167What this trial is testingTesting AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)Who this might be right forAdvanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more National Cancer Institute (NCI) 19
Testing effectiveness (Phase 2)Study completedNCT03544814What this trial is testingEGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual ProgressionWho this might be right forLung AdenocarcinomaEGFR Activating Mutation Shanghai Chest Hospital 99
Testing effectiveness (Phase 2)Looking for participantsNCT07079475What this trial is testingStudy of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)Who this might be right forNon-Small Cell Lung Cancer Dizal (Jiangsu) Pharmaceutical Co., Ltd. 200
Testing effectiveness (Phase 2)Looking for participantsNCT06728865What this trial is testingEvaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical StudyWho this might be right forNon-small Cell Lung Cancer (NSCLC)EGFR Mutation-Positive Lung CancerBrain Metastases+2 more Li-kun Chen 70
Testing effectiveness (Phase 2)Looking for participantsNCT06563999What this trial is testingNeoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.Who this might be right forLung Cancer Stage IIIMutation Sun Yat-sen University 120
Not applicableEnded earlyNCT02483416What this trial is testingEvaluation of the Impact of Nurse-led Telephone on Treatment ComplianceWho this might be right forCarcinoma, Non-Small-Cell Lung Boehringer Ingelheim 30
Early research (Phase 1)Study completedNCT00903734What this trial is testingAn Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation StatusWho this might be right forAdvanced Cancers M.D. Anderson Cancer Center 16
Testing effectiveness (Phase 2)Study completedNCT01167244What this trial is testingTrial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior ResponseWho this might be right forNon-Small-Cell Lung Carcinoma Bristol-Myers Squibb 11
Testing effectiveness (Phase 2)UnknownNCT01714908What this trial is testingPhase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21Who this might be right forNon-small Cell Lung Cancer Jinming Yu 100
Large-scale testing (Phase 3)Looking for participantsNCT07183189What this trial is testingSHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLCWho this might be right forNon-small Cell Lung Cancer Suzhou Suncadia Biopharmaceuticals Co., Ltd. 576
Testing effectiveness (Phase 2)Ended earlyNCT02595840What this trial is testingBiomarker Study Accompanying the AIO-TRK-0114 Study (MARBLE)Who this might be right forNon-small-cell Lung Cancer With Somatic EGFR Mutations Universität Duisburg-Essen 4
Testing effectiveness (Phase 2)Active Not RecruitingNCT06194448What this trial is testingTo Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR MutationsWho this might be right forLung Cancer AstraZeneca 76
Large-scale testing (Phase 3)Ended earlyNCT04816214What this trial is testingStudy Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line TherapyWho this might be right forCarcinoma, Non-Small-Cell Lung Novartis Pharmaceuticals 6
Not applicableUnknownNCT05136014What this trial is testingEvaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid ModelWho this might be right forLung CancerLung AdenocarcinomaEGFR Activating Mutation+2 more Central Hospital, Nancy, France 200
Post-approval studies (Phase 4)UnknownNCT04132102What this trial is testingTo Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive MutationWho this might be right forLung Squamous Cell Carcinoma Shanghai Chest Hospital 20
Not applicableEnrolling By InvitationNCT06730477What this trial is testingPlasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung AdenocarcinomaWho this might be right forLung AdenocarcinomaEGFR Activating Mutation Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 500
Early research (Phase 1)Study completedNCT04959981What this trial is testingAnti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLCWho this might be right forAdvanced Non-squamous Non-small-cell Lung Cancer Erasca, Inc. 24
Large-scale testing (Phase 3)Ended earlyNCT02588261What this trial is testingASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating MutationsWho this might be right forNon-small Cell Lung Cancer (NSCLC) Astellas Pharma Global Development, Inc. 530